Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors

Epilepsy Research

Volumn 44, Issue 1, 2001, Pages 71-82

  Nelson, M H ^a   Birnbaum, A K ^a   Remmel, R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anti epileptic drugs; Drug interactions; Human liver microsomes; Phenytoin; Selective serotonin re uptake inhibitors

Indexed keywords

4 HYDROXYPHENYL PHENYL HYDANTOIN; 4' HYDROXY DICLOFENAC; ATENOLOL; CYTOCHROME P450 2C9; DICLOFENAC; DICLOFENAC DERIVATIVE; DIGOXIN; FLUOROURACIL; FLUOXETINE; HYDANTOIN DERIVATIVE; M PROTEIN; MORPHINE SULFATE; NORFLUOXETINE; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; CATALYSIS; CAUSE OF DEATH; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HYDROXYLATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; METABOLITE; NEUROTRANSMITTER UPTAKE; PRESCHOOL CHILD; PRIORITY JOURNAL; REACTION ANALYSIS;

AGED; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; FLUOXETINE; HUMANS; HYDROXYLATION; MALE; MICROSOMES, LIVER; MIDDLE AGED; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0035095338     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00203-5     Document Type: Article

References (35)

1. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin in its major metabolite
2. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
3. Age and phenytoin kinetics in adult epileptics
4. Allelic and functional variability of cytochrome P4502C9
5. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
6. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochrome P-450
7. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and in man
8. Antiepileptics in the elderly: Pharmacoepidemiology and pharmacokinetics
9. Interaction between phenytoin and fluoxetine
10. Pharmacogenetics and drug metabolism of newer antidepressant agents
11. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes
12. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder
13. Study of dose-dependent metabolism of 5,5-diphenyl-hydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro
14. Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions
15. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities
16. A review of the metabolism of paroxetine in man
17. Antiepileptic drug use in nursing home residents: Effect of age, gender, and comedication on patterns of use
18. Fluoxetine, a selective serotonin-reuptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltoride (LY201116)
19. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver
20. Fluoxetine: Clinical pharmacology and physiologic disposition
21. Rational approach to the prediction of drug interactions among antiepileptic drugs
22. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP 2C9
23. 3]-phenytoin from plasma obtained from pulse dose pharmacokinetic studies
24. The carbon monoxide-binding pigment of liver microsomes
25. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline
26. Clinically relevant pharmacology of selective serotonin reuptake inhibitors
27. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
28. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
29. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation
30. Fluoxetine inhibition of phenytoin metabolism
31. Selective serotonin reuptake inhibitors and CNS drug interactions
32. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
33. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo
34. Interaction of phenytoin and fluoxetine
35. Differential inhibitory effects of phenytoin, diclofenac, phenylbutazone and a series of sulfonamides on hepatic cytochrome P4502C activity in vitro, and correlation with some molecular descriptors in the dwarf goat (Caprus hircus aegagrus)